Y mAbs Therapeutics — Technical Presentation (May 2025)
49 slides from Y mAbs Therapeutics's technical presentation, May 28, 2025
Slide 1: Radiopharmaceutical R&D Update May 28, 2025
Radiopharmaceutical R&D Update May 28, 2025
Slide 2: Disclaimer: Forward-Looking Statements
Disclaimer Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the US Private Securities Litigation Reform Act of 1995 . The forward - looking statements involve substantial risks and uncertainties . All statements, other than statements of hist
Slide 3: Today's Presenters
Today’s Presenters Mike Rossi President and Chief Executive Officer Natalie Tucker SVP, Radiopharmaceutical Business Unit Head Norman LaFrance, MD Chief Medical and Development Officer 3 Additional Team Members Available During Q&A
Slide 4: Y-mAbs is a Commercial Biopharmaceutical Company with Two Business Units
Y - mAbs is a Commercial Biopharmaceutical Company with Two Distinct Business Units: DANYELZA and Radiopharmaceuticals 4 DANYELZA RADIOPHARMACEUTICALS
Slide 5: Our Vision for Growth
Our VISION for GROWTH 5 Deliver on Promise of Radiopharmaceuticals with Minimal O ff - Target E ffects Fully Operational Theranostic Platform Proprietary Radiohaptens Enabling Multiple Isotope Modularity Investment Favors Development, NOT CAPEX Physician Participation Along the Treatment Journey
Slide 6: Positioned to Potentially Disrupt the Existing Approach to Radiopharmaceuticals
We are Positioned to Potentially Disrupt the Existing Approach to Radiopharmaceuticals by Addressing Key Obstacles that Limit Commercial Utilization Leverage Existing Infrastructure • Assembly occurs in vivo • Reduced COGS and overhead Patient - Centric Targeting • Modular design enables isotope fle
Slide 7: Multiple Potential High Value Inflection Points Anticipated Ahead
7 Radiopharmaceuticals: Multiple Potential High Value Inflection Points Anticipated Ahead Increasing commitment, capabilities, and leadership in Radiopharmaceuticals 2025 2026 2027 Realignment into two business units: DANYELZA and Radiopharmaceuticals CD38 - SADA FPI in 1H 2025 GD2 - SADA Trial 1001
Slide 8: Today's Agenda: Three Key Radiopharmaceutical Updates
8 Today’s Agenda: Three Key Radiopharmaceutical Updates 1. Trial 1001 Part A – Complete 2. Key Learnings from Molecule Optimization Studies 3. Expanded Development Pipeline Y - mAbs Development
Slide 9: Recent Insights Will Be Scaled Across the Platform
9 Recent Insights Will Be Scaled Across the Platform 1 Met primary objective demonstrating GD2 - SADA - 177 Lu - DOTA is safe and well tolerated 2 GD2 - SADA PK was predicted and with close interpatient cohort repeatability 3 Identified opportunities to streamline study designs and improve operation
Slide 10: Today's Agenda: Three Key Radiopharmaceutical Updates
10 Today’s Agenda: Three Key Radiopharmaceutical Updates 1. Trial 1001 Part A – Complete 2. Key Learnings from Molecule Optimization Studies 3. Expanded Development Pipeline Y - mAbs Development
Slide 11: Trial 1001 Phase 1 Clinical Trial Background
GD2 - SADA Trial 1001 Phase 1 Clinical Trial Background 11
Slide 12: Phase 1 Trial 1001, Part A: Study Objectives and Design
12 Cohort 6 Cohort 5 Cohort 4 Cohort 3 Cohort 2 Cohort 1 1 mg/kg 1 mg/kg 3 mg/kg 1 mg/kg 0.3 mg/kg 0.3 mg/kg GD2 - SADA 3 4 5 5 2 5 Interval (days) • Primary : Establish safety of GD2 - SADA • Secondary : Evaluate dosimetry, PK, and immunogenicity profiles of GD2 - SADA - 177 Lu - DOTA • HR - NB (≥1
Slide 13: Part A Treatment Regimen: Imaging Stage and Treatment Stage
13 Part A Treatment Regimen Was Based on Tumors Selected by CT and Included an Imaging Stage Followed by a Treatment Stage Day 1 GD2 - SADA Protein 0.3, 1.0, or 3.0 mg/kg Day 3+ 177 Lu - DOTA 30 mCi Nuclear Imaging Determination of tumor uptake (in 5 prev. selected) Blood was collected at serial tim
Slide 14: Patient Demographics
Patient Demographics 14
Slide 15: Patients Treated with the Complex: Enrollment Flow
15 A Total of 22 Patients Were Treated with the GD2 - SADA - 177 Lu - DOTA Complex Patients screened 31 Screen failures ( i. e., no measurable disease, lab values out of inclusion and serious intercurrent illness) 8 Withdrawal from study post Grade 3 AE after first GD2 - SADA protein dose 1 No tumor
Slide 16: Patients Were Heavily Pretreated and Similarly Distributed Across Cohorts
16 Patients Were Heavily Pretreated and Similarly Distributed Across Cohorts Program: t_demog.sas - output: t_demog.rtf - executed: 24APR2025 – data cutoff 22APR2025 N: Number of patients, BMI: Body mass index, ECOG: Eastern Cooperative Oncology Group Performance Status Scale, SCLC: Small - Cell Lun
Slide 17: Patients in Imaging Stage Showed Positive Tumor Uptake
17 9 Patients in the Imaging Stage Showed Positive Tumor Uptake Per Protocol Design and Were Eligible for Treatment Stage Overview of patients who showed tumor uptake Cohort 6 (3 - day interval) Cohort 6 (3 - day interval) Cohort 6 (3 - day interval) Cohorts 5 (4 - day interval) Cohort 4 (5 - day in
Slide 18: Safety Summary
Safety Summary 18
Slide 19: Safety Summary: Part A Safe and Well-Tolerated
19 Safety Summary : Part A was Safe and Well - Tolerated Across Both GD2 - SADA and 177 Lu - DOTA Administrations • No AE trends across all dosing cohorts • No DLTs or treatment - related serious adverse events • Treatment related adverse events were mostly CTCAE grade 1 (70%) and 2 (27.5%) • ADA di
Slide 20: Manageable Safety Profile: No DLTs, No Treatment-Related SAEs
20 Manageable Safety Profile: No DLTs, No Treatment - related SAEs 0 3 8 16 123 128 0 1 0 1 40 40 0 20 40 60 80 100 120 140 DLT AESI SAE Grade 3+ Any TEAE Any AE Number of Events Adverse Event Type Related AE All AE TEAE: Treatment - emergent adverse event Grade 3+: Common terminology criteria for a
Slide 21: Nausea, Chills Were the Most Common Related Adverse Events
21 Nausea, Chills Were the Most Common Related Adverse Events 0 1 2 3 4 5 6 7 8 9 10 Nausea Lymphocyte count decreased Constipation Abdominal pain Arthralgia Back pain Chills Hypoalbuminaemia Hyponatraemia Pain in extremity Decreased appetite Fatigue TEAEs with a total frequency ≥ 10% N E 2 2 2 2 2
Slide 22: No Dose-Dependent AE Trends; AESI Were Non-Serious
22 No Dose - Dependent AE Trends as Seen With GD2 Therapies or Radiopharmaceuticals; AESI Were Non - Serious Patient 1, AESI 1: Abdominal Pain 3 Adverse Events of Special Interest (AESI) in 2 Patients Patient 2, AESIs 2 & 3: Liver Function 5: 1 mg/kg, 4 - day interval Cohort # Hx of elevated liver e
Slide 23: Pharmacokinetics (PK)
GD2 - SADA Pharmacokinetics (PK) 23
Slide 24: Pharmacokinetics Outline the Optimal Clearance Interval
24 Pharmacokinetics of GD2 - SADA Outline the Optimal Clearance Interval for Maximum Tumor - to - Kidney Ratio • Allometric scaling was used to model human GD2 - SADA PK based on preclinical data • GD2 - SADA blood trough was identified preclinically , i.e., lowest amount of GD2 - SADA in blood prio
Slide 25: Pharmacokinetics are Dose Dependent and Predictably Follow Modeling
25 GD2 - SADA Pharmacokinetics are Dose Dependent and Predictably Follow Modeling Source: Trial: Y - mAbs 1001 DMC. 06May2025 Note: Serum levels of GD2 - SADA were measured over time N=22: One patient who withdrew prior to 177 Lu - DOTA administration did not continue with PK sampling • The initial
Slide 26: Dose Normalized PK Displayed Proportional Cmax and Clearance Rates
26 Dose Normalized GD2 - SADA PK Displayed Proportional Cmax and Clearance Rates over Three Administered Dose Concentrations Source: Trial: Y - mAbs 1001. f_median_sada.rtf - 05May2025 Note: Serum levels of GD2 - SADA were measured over time, normalized by mg/kg of GD2 - SADA protein Time (hours) GD
Slide 27: Lu-DOTA Pharmacokinetics (PK)
177 Lu - DOTA Pharmacokinetics (PK) 27
Slide 28: Lu-DOTA PK is a Function of Protein Concentration and Clearance Interval
177 Lu - DOTA PK is a Function of the GD2 - SADA Protein Concentration and Clearance Interval Allowing the Optimization of Therapeutic Index 28 Note: Pre - dose GD2 - SADA concentration is assigned a value of 10, as it is 0 ng/mL for all included records • Higher concentrations of GD2 - SADA in seru
Slide 29: Lu-DOTA PK by Cohort Illustrates Dual Impact of Concentration and Interval
177 Lu - DOTA PK by Cohort Illustrates Dual Impact of GD2 - SADA Concentration and Clearance Interval 29 Note: Pre - dose GD2 - SADA concentration is assigned a value of 10, as it is 0 ng/mL for all included records 177 Lu - DOTA PK by Cohort (safety analysis set) 177 Lu - DOTA • Multiple protein do
Slide 30: Lu-DOTA Dosimetry
GD2 - SADA - 177 Lu - DOTA Dosimetry 30
Slide 31: Tumor Uptake Restricted to Site Selected Target Lesions; Expanded Evaluation
31 Per Protocol, Tumor Uptake Was Restricted to Site Selected Target Lesions Identified via CT; Expanded Evaluation Included All Tumors OLINDA/EXM 2.2 (Organ Level INternal Dose Assessment/ EXponential Modeling), Hermes Medical Solutions Expanded Evaluation Per Protocol Evaluation Next generation im
Slide 32: Per Protocol Evaluation: Patients with Tumor Uptake
32 Per Protocol Evaluation: 9 of 22 Patients Were Identified as Having Tumor Uptake Patient 021 Patient 019 Patient 018 Patient 016 Patient 011 Patient 009 Patient 008 Patient 005 Patient 003 6 6 6 5 4 3 3 3 2 Cohort 1.0 1.0 1.0 1.0 3.0 1.0 1.0 1.0 0.3 GD2 - SADA protein dose (mg/kg) 3 3 3 4 5 5 5 5
Slide 33: Per Expanded Evaluation: 16 of 22 Patients Showed Tumor Uptake
33 Note: All data based on 30mCi 177 LuDOTA diagnostic dose; Gy represents absorbed dose; column colors represents cohorts Patient 21 (pending analysis ): positive tumor uptake confirmed, dosimetry calculations on hold pending receipt of additional imaging data (CT scan ) Patient 22 (pending analysi
Slide 34: Per Expanded Evaluation: Patients Showed Tumor Uptake, Increased Gray per Tumor
34 Per Expanded Evaluation : 16 of 22 Patients Showed Tumor Uptake, Largely Presenting with Increased Gray per Tumor Patient 022 Patient 017 Patient 015 Patient 014 Patient 013 Patient 006 Patient 004 Patient 021 Patient 019 Patient 018 Patient 016 Patient 011 Patient 009 Patient 008 Patient 005 Pat
Slide 35: Protocol Artificially Restrained Tumor Selection
35 Protocol Artificially Restrained Tumor Selection and Resulted in Additional Tumors with Dose Uptake Excluded from Evaluation Positive Patient: Nontarget Lesion with Uptake Patient ### - ## - #### - 011: Cohort 5, 1 mg/kg GD2 - SADA + 3 - day clearance interval, Uveal Melanoma Patient continued on
Slide 36: Implication to Platform: 1001 Part A Key Learning
36 Implication to Platform 1001 Part A – Key Learning Accelerate trial with parallel cohorts, single variable modifications; leverage protein PK to determine dosing interval FiH demonstration of SADA shown to be safe and well tolerated with predictable PK* 1 Utilize central review of Nuclear Images
Slide 37: Today's Agenda: Three Key Radiopharmaceutical Updates
37 Today’s Agenda: Three Key Radiopharmaceutical Updates 1. Trial 1001 Part A – Complete 2. Key Learnings from Molecule Optimization Studies 3. Expanded Development Pipeline Y - mAbs Development
Slide 38: Two Studies in Q1 2025 to Identify Opportunities to Improve Tumor Uptake
38 Two Studies Were Conducted in Q1 2025 to Evaluate GD2 - SADA Complex and Identify Opportunities to Improve Tumor Uptake Current Molecule Improved Molecule Y - mAbs 20 pmole (DOTA) Current Molecule Improved Molecule TUMOR KIDNEY Y - mAbs 20 pmole (DOTA) Current Molecule Improved Molecule TUMOR Y -
Slide 39: Improved Molecule Will Consist of a New Radiohapten and Modified Specific Activity
39 Improved Molecule W ill C onsist of a New Radiohapten and Modified S pecific A ctivity No Change Necessary Change to New Proprietary Radiohapten Change to low Specific Activity (SA) / High Mass No change enables use of existing manufactured protein x Formulation 177 Lu - DOTA Protein Improved tum
Slide 40: New Radiohapten Expands Access to a Range of Isotopes
40 New Radiohapten Expands Access to a Range of Isotopes with Theranostic Applications, Including Alphas and PET Proprietary R adiohapten creates a “universal linker” to accommodate all payloads with picomolar affinity to anti - DOTA in SADA BsAB (with rapid clearance into the urine) NEW - Proprieta
Slide 41: Improved Molecule Incorporated into a Bridge Study in 1H 2026
The Improved Molecule Will be Incorporated into a Bridge Study in 1H 2026 * Through a Proposed Amendment ** to the Current IND 1H 2026 – 2H 2026 * • Confirm safety of new Radiohapten in humans • Assess impact of Radiohapten and mass dose on therapeutic index • Optimize clearance intervals (longer re
Slide 42: Today's Agenda: Three Key Radiopharmaceutical Updates
42 Today’s Agenda: Three Key Radiopharmaceutical Updates 1. Trial 1001 Part A – Complete 2. Key Learnings from Molecule Optimization Studies 3. Expanded Development Pipeline Y - mAbs Development
Slide 43: Systemic Evaluation to Identify Optimal Targets for the Platform
43 We Conducted a Systemic Evaluation to Identify Optimal Targets for the Y - mAbs Platform and Narrowed Selection in 3 Phases 15 Prioritized Targets Staged over Few Years Broad Target Universe Initial refinement – Cancer types of interest (24 cancer types) Second refinement – Tumor Refinement (675
Slide 44: Targets Phased Across Years, Focused on Three Franchises
44 The Targets Were Phased Across 3 Years, with the Early Years Focused on Derisking the Innovative Platform …and strategic diversification of pipeline expansion Gastrointestinal Lung Women’s Cancers Targets are Focused on Three Franchise Opportunities 2027 2026 2025 e.g. SCLC, NSCLC, TNBC, Ovarian,
Slide 45: Our Radiopharmaceutical Pipeline
45 Our Radiopharmaceutical Pipeline THERAPEUTIC PIPELINE Phase 2 Phase 1 Preclinical R&D Isotope Asset 177 Lu GD2 - SADA - 177 Lu - Proteus R/R SCLC, Sarcoma, Malignant Melanoma, HR Neuroblastoma GD2 177 Lu CD38 - SADA R/R Non - Hodgkin Lymphoma CD38 Ac225 Antibody Colorectal Cancer Undisclosed Alph
Slide 46: Multiple Potential High Value Inflection Points Anticipated Ahead
46 Radiopharmaceuticals: Multiple Potential High Value Inflection Points Anticipated Ahead Increasing commitment, capabilities, and leadership in Radiopharmaceuticals 2025 2026 2027 Realignment into two business units: DANYELZA and Radiopharmaceuticals CD38 - SADA FPI in 1H 2025 GD2 - SADA Trial 100
Slide 47: In Conclusion: Recent Insights Will Be Scaled Across the Platform
47 In Conclusion: Recent Insights Will Be Scaled Across the Platform GD2 - SADA Protein is safe and well - tolerated Protein PK and dosing interval optimize the Therapeutic Index New Universal Radiohapten expected to modularize the platfor m, allow for multiple isotopes, and improve tumor retention
Slide 48: Y-mAbs Therapeutics, Inc.
Therapeu! itics, Inc.
Slide 49: Thank You
Thank You 49
Y-mAbs Therapeutics — Technical Presentation (May 2025) on 6ix